Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-053347

Chief Accounting Officer sold 715 shares at an average $1.56 ($1,116)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hagen Brett R · Chief Accounting Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-10-19 Sale : show line 1 in the form 10b5-1 −358 $1.58 $566 126,595 D
2023-10-20 Sale : show line 2 in the form 10b5-1 −357 $1.54 $550 126,238 D
Open-market sales · 715 sh · avg $1.56 · $1,116
Loading xslF345X05/doc4.xml…